<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25792507</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1475-6374</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Journal of enzyme inhibition and medicinal chemistry</Title><ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation></Journal><ArticleTitle>Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study.</ArticleTitle><Pagination><StartPage>332</StartPage><EndPage>339</EndPage><MedlinePgn>332-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/14756366.2015.1018245</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a highly infectious pathogen primarily responsible for Hand, Foot, and Mouth Disease, particularly among children. Currently, no approved antiviral drug has been developed against this disease. The EV71 3C protease is deemed an attractive drug target due to its crucial role in viral polyprotein processing. Rupintrivir, a peptide-based inhibitor originally developed to target the human rhinovirus 3C protease, was found to inhibit the EV71 3C protease. In this communication, we report the inhibitory activities of 30 Rupintrivir analogs against the EV71 3C protease. The most potent inhibitor, containing a P2 ring-constrained phenylalanine analog (compound 9), was found to be two-fold more potent than Rupintrivir (IC50 value 3.4&#x2009;&#xb1;&#x2009;0.4 versus 7.3&#x2009;&#xb1;&#x2009;0.8&#x2009;&#x3bc;M). Our findings suggest that employing geometrically constrained residues in peptide-based protease inhibitors can potentially enhance their inhibitory activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Melgious J Y</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Qiu Ying</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Fui Mee</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Then</LastName><ForeName>Siew Wen</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulsen</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheong</LastName><ForeName>Yuen Kuen</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngoh</LastName><ForeName>Zi Xian</ForeName><Initials>ZX</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yong Wah</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>b Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR) , Singapore , and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Jianhe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin J H</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>b Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR) , Singapore , and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology , National University of Singapore , Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>C S Brian</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>a Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR) , Singapore .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Enzyme Inhib Med Chem</MedlineTA><NlmUniqueID>101150203</NlmUniqueID><ISSNLinking>1475-6366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057786">Peptidomimetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RGE5K1Q5QW</RegistryNumber><NameOfSubstance UI="C118874">rupintrivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="N">3C Viral Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060326" MajorTopicYN="N">Chemistry Techniques, Synthetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057786" MajorTopicYN="N">Peptidomimetics</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="Y">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3C protease</Keyword><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">Rupintrivir</Keyword><Keyword MajorTopicYN="N">peptide-based inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25792507</ArticleId><ArticleId IdType="doi">10.3109/14756366.2015.1018245</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>